NHS England has announced a policy blocking new referrals for gender-affirming hormone therapy for transgender youth under 18, effective from March 9. This decision will undergo a 90-day consultation period, after which a longer-term policy will be introduced. The restriction prevents clinicians from initiating new referrals but allows those already undergoing treatment to continue. However, this only applies to public healthcare under NHS England and does not impact private healthcare providers or practices in other parts of the UK.
This decision raises concerns about restricting access to individualized care, as medical treatment for adolescents is typically customized to the needs of each patient. The blanket prohibition on referrals contradicts established clinical practices, where gender-affirming hormone therapy is considered a best practice for some transgender youth, following comprehensive psychological assessments and obtaining informed consent. Clinical guidelines also support hormone therapy, as research shows its effectiveness in reducing gender dysphoria and improving mental health outcomes, including decreased suicidality.
The move follows the 2024 Cass Review, a government-commissioned study that recommended restricting gender-affirming care. However, the review’s methodology and conclusions have been criticized by medical professionals. The NHS has also restricted access to puberty-delaying medications to clinical trials, a move also condemned by the British Medical Association. Puberty blockers are considered reversible and offer transgender youth more time to explore their gender identity before making further treatment decisions.
Transgender youth in England have long faced significant barriers to healthcare, with long wait times for appointments at state-run clinics. The new policy further compounds these challenges, restricting access to evidence-based, gender-affirming care and undermining the rights of transgender youth to health, bodily autonomy, and nondiscrimination. Advocates are calling for NHS England to reverse the decision and restore access to necessary care.
